Cheng H, Perez-Soler R (2018) Leptomeningeal metastases in non-small-cell lung cancer. Lancet Oncol 19(1):e43–e55. https://doi.org/10.1016/S1470-2045(17)30689-7

Article  PubMed  Google Scholar 

Morris PG, Reiner AS, Szenberg OR et al (2012) Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. J Thorac Oncol 7(2):382–385. https://doi.org/10.1097/JTO.0b013e3182398e4f

Article  PubMed  Google Scholar 

Seong M, Park S, Kim ST et al (2020) Diagnostic accuracy of MR imaging of patients with leptomeningeal seeding from lung adenocarcinoma based on 2017 RANO proposal: added value of contrast-enhanced 2D axial T2 FLAIR. J Neurooncol 149(2):367–372. https://doi.org/10.1007/s11060-020-03617-2

Article  PubMed  Google Scholar 

Ozcan G, Singh M, Vredenburgh JJ (2023) Leptomeningeal metastasis from non-small cell lung cancer and current landscape of treatments. Clin Cancer Res 29(1):11–29. https://doi.org/10.1158/1078-0432.CCR-22-1585

Article  CAS  PubMed  Google Scholar 

Le Rhun E, Weller M, Brandsma D, EANO Executive Board and ESMO Guidelines Committee et al (2017) EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up of patients with leptomeningeal metastasis from solid tumors. Ann Oncol 28(suppl_4):iv84–iv99. https://doi.org/10.1093/annonc/mdx221

Xu Y, Hu M, Zhang M et al (2018) Prospective study revealed prognostic significance of responses in leptomeningeal metastasis and clinical value of cerebrospinal fluid-based liquid biopsy. Lung Cancer 125:142–149. https://doi.org/10.1016/j.lungcan.2018.08.017

Article  PubMed  Google Scholar 

Yang JCH, Kim SW, Kim DW et al (2020) Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: the BLOOM Study. J Clin Oncol 38(6):538–547. https://doi.org/10.1200/JCO.19.00457

Article  CAS  PubMed  Google Scholar 

Pellerino A, Brastianos PK, Rudà R, Soffietti R (2021) Leptomeningeal metastases from solid tumors: recent advances in diagnosis and molecular approaches. Cancers (Basel) 13(12):2888. https://doi.org/10.3390/cancers13122888

Article  CAS  PubMed  Google Scholar 

Park S, Lee MH, Seong M et al (2020) A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy. Ann Oncol 31(10):1397–1404. https://doi.org/10.1016/j.annonc.2020.06.017

Article  CAS  PubMed  Google Scholar 

Naidoo J, Schreck KC, Fu W et al (2021) Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers. J Immunother Cancer. https://doi.org/10.1136/jitc-2021-002473

Grossman SA, Finkelstein DM, Ruckdeschel JC et al (1993) Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. J Clin Oncol 11(3):561–569. https://doi.org/10.1200/JCO.1993.11.3.561

Glantz MJ, Jaeckle KA, Chamberlain MC, Phuphanich S et al (1999) A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 5(11):3394–3402

CAS  PubMed  Google Scholar 

Hitchins RN, Bell DR, Woods RL, Levi JA (1987) A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol 5(10):1655–1662. https://doi.org/10.1200/JCO.1987.5.10.1655

Article  CAS  PubMed  Google Scholar 

Le Rhun E, Wallet J, Mailliez A et al (2020) Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for newly diagnosed leptomeningeal metastasis from breast cancer. Neuro Oncol 22(4):524–538. https://doi.org/10.1093/neuonc/noz201

Article  CAS  PubMed  Google Scholar 

Boogerd W, van den Bent MJ, Koehler PJ et al (2004) The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomized study. Eur J Cancer 40(18):2726–2733. https://doi.org/10.1016/j.ejca.2004.08.012

Article  CAS  PubMed  Google Scholar 

Shapiro WR, Schmid M, Glantz M, Miller JJ (2006) A randomized phase III/ IV study to determine benefit and safety of cytarabine liposome injection for treatment of neoplastic meningitis. J Clin Oncol 24(18_suppl):1528. https://doi.org/10.1200/jco.2006.24.18_suppl.1528

Article  Google Scholar 

Pan Z, Yang G, Cui J et al (2019) A pilot phase 1 study of intrathecal pemetrexed for refractory leptomeningeal metastases from non-small-cell lung cancer. Front Oncol 9:838. https://doi.org/10.3389/fonc.2019.00838

Article  PubMed  PubMed Central  Google Scholar 

Fan C, Zhao Q, Li L et al (2021) Efficacy and safety of intrathecal pemetrexed combined with dexamethasone for treating tyrosine kinase inhibitor-failed leptomeningeal metastases from EGFR-mutant NSCLC—a prospective, open-label, single-arm phase 1/2 clinical trial (unique identifier: ChiCTR1800016615). J Thorac Oncol 16(8):1359–1368. https://doi.org/10.1016/j.jtho.2021.04.018

Article  CAS  PubMed  Google Scholar 

Pan Z, Yang G, He H et al (2020) Intrathecal pemetrexed combined with involved-field radiotherapy as a first-line intra-CSF therapy for leptomeningeal metastases from solid tumors: a phase I/II study. Ther Adv Med Oncol 12:1758835920937953. https://doi.org/10.1177/1758835920937953

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun JM, Nam MH, Chung JY et al (2011) Safety and pharmacokinetics of intrathecal administration of pemetrexed in rats. Cancer Chemother Pharmacol 68(2):531–538. https://doi.org/10.1007/s00280-010-1522-7

Article  CAS  PubMed  Google Scholar 

Wen PY, Chang SM, Van den Bent MJ et al (2017) Response Assessment in Neuro-Oncology clinical trials. J Clin Oncol 35(21):2439–2449. https://doi.org/10.1200/JCO.2017.72.7511

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chamberlain M, Soffietti R, Raizer J et al (2014) Leptomeningeal metastasis: a Response Assessment in Neuro-Oncology critical review of endpoints and response criteria of published randomized clinical trials. Neuro Oncol 16(9):1176–1185. https://doi.org/10.1093/neuonc/nou089

Article  CAS  PubMed  PubMed Central  Google Scholar 

Le Rhun E, Devos P, Boulanger T et al (2019) The RANO Leptomeningeal Metastasis Group proposal to assess response to treatment: lack of feasibility and clinical utility and a revised proposal. Neuro Oncol 21(5):648–658. https://doi.org/10.1093/neuonc/noz024

Article  PubMed  PubMed Central  Google Scholar 

Kwon BS, Cho YH, Yoon SK et al (2020) Impact of clinicopathologic features on leptomeningeal metastasis from lung adenocarcinoma and treatment efficacy with epidermal growth factor receptor tyrosine kinase inhibitor. Thorac Cancer 11(2):436–442. https://doi.org/10.1111/1759-7714.13296

Article  CAS  PubMed  PubMed Central  Google Scholar 

Le Rhun E, Devos P, Weller J et al (2021) Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors. Neuro Oncol 23(7):1100–1112. https://doi.org/10.1093/neuonc/noaa298

Article  PubMed  Google Scholar 

Ramotar M, Barnes S, Moraes F et al (2020) Neurological death is common in patients with EGFR mutant non-small cell lung cancer diagnosed with brain metastases. Adv Radiat Oncol 5(3):350–357. https://doi.org/10.1016/j.adro.2019.11.002

Article  PubMed  Google Scholar